NewsPanacea Biotec Receives Rectified Assessment Order, Tax Liability Reduced to Nil for AY 2016-17Panacea Biotec Receives Rectified Assessment Order, Tax Liability Reduced to Nil for AY 2016-17
Panacea Biotec Limited has received a rectified assessment order from the Deputy Commissioner of Income Tax, New Delhi, dated April 06, 2026, which has reduced the company's tax liability for Assessment Year 2016-17 to nil. The original assessment order dated March 01, 2026, had imposed a demand of ₹10.23 crore due to disallowed expenditures. Following the company's rectification application, errors including double addition of disallowances and omission of set-off for brought-forward losses were corrected, resulting in a positive financial impact with no adverse effects expected on the company's operations.
*this image is generated using AI for illustrative purposes only.
Panacea Biotec Limited has successfully obtained relief from a significant tax demand after receiving a rectified assessment order from the Income Tax Department. The company disclosed this development to stock exchanges on April 07, 2026, under regulatory compliance requirements.
Rectification Application Success
The pharmaceutical company had previously faced a tax demand of ₹10.23 crore for Assessment Year 2016-17 following an assessment order dated March 01, 2026, issued by the Deputy Commissioner of Income Tax (DCIT), New Delhi. The original order had disallowed certain expenditures, leading to the substantial demand.
In response, Panacea Biotec filed a rectification application under the Income Tax Act, 1961, to address what the company identified as errors apparent from the record. The application specifically targeted two key issues: double addition of disallowances and the omission of set-off for brought-forward losses.
Assessment Order Details
| Parameter: | Details |
|---|---|
| Rectified Order Date: | April 06, 2026 |
| Issuing Authority: | Deputy Commissioner of Income Tax, New Delhi |
| Assessment Year: | 2016-17 |
| Original Demand: | ₹10.23 crore |
| Revised Tax Liability: | Nil |
Financial Impact and Implications
The rectified assessment order has resulted in a positive financial impact for the company. According to the disclosure, the rectification has successfully nullified the entire tax demand for AY 2016-17. The company has stated that it does not foresee any adverse impact on its financial, operational, or other activities arising from this order.
The rectification addressed specific computational errors in the original assessment, including:
- Correction of double addition of disallowances
- Proper set-off of brought-forward losses
- Elimination of errors apparent from the record
Regulatory Compliance
The company made this disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made in continuation of the company's earlier communication dated March 06, 2026, when it had initially informed exchanges about the original demand order.
Ankit Jain, General Manager – Legal & Company Secretary, signed the disclosure documents on behalf of Panacea Biotec Limited. The company has provided comprehensive details as required under SEBI regulations, including the nature of communication received, expected financial implications, and relevant timelines for the assessment year in question.
Historical Stock Returns for Panacea Biotec
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.09% | +2.09% | +3.64% | -22.97% | -25.17% | +41.80% |
Will this successful rectification strategy influence Panacea Biotec's approach to handling other pending tax assessments or disputes?
How might this ₹10.23 crore tax relief impact Panacea Biotec's cash flow and investment plans for upcoming quarters?
Could this rectification outcome set a precedent for other pharmaceutical companies facing similar double disallowance issues with the Income Tax Department?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
